NYSE · LLY
Healthcare · Drug Manufacturers - General
$1,115.70
Down-$7.75 (-0.69%)
Updated Sep 13, 2026, 5:19 PM
SID Score
5.4/10
Composite research score
Smart Money
46/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
LLY closed at $1,115.70 after 19 trading sessions, down 5.70% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $1,129.405 | $1,131.44 | $1,113.2919 | $1,115.70 | 1.84M |
| Sep 10, 2026 | $1,126.08 | $1,133.79 | $1,120.52 | $1,123.00 | 2M |
| Sep 9, 2026 | $1,127.61 | $1,138.79 | $1,119.00 | $1,124.21 | 2.05M |
| Sep 8, 2026 | $1,133.00 | $1,134.53 | $1,113.55 | $1,123.91 | 2.4M |
| Sep 4, 2026 | $1,150.61 | $1,158.44 | $1,138.306 | $1,149.36 | 2.22M |
| Sep 3, 2026 | $1,170.00 | $1,171.66 | $1,137.50 | $1,159.60 | 2.55M |
| Sep 2, 2026 | $1,164.15 | $1,187.83 | $1,158.00 | $1,160.08 | 2.45M |
| Sep 1, 2026 | $1,188.00 | $1,188.325 | $1,156.8501 | $1,160.00 | 2.52M |
| Aug 31, 2026 | $1,168.47 | $1,171.4479 | $1,147.00 | $1,156.73 | 3.06M |
| Aug 28, 2026 | $1,172.66 | $1,180.00 | $1,162.93 | $1,174.61 | 2.45M |
| Aug 27, 2026 | $1,182.25 | $1,190.11 | $1,171.71 | $1,176.10 | 2.74M |
| Aug 26, 2026 | $1,234.00 | $1,235.775 | $1,180.01 | $1,189.41 | 3.01M |
| Aug 25, 2026 | $1,249.00 | $1,264.73 | $1,229.79 | $1,233.66 | 2.14M |
| Aug 24, 2026 | $1,262.14 | $1,262.14 | $1,230.95 | $1,246.93 | 1.67M |
| Aug 21, 2026 | $1,232.00 | $1,271.22 | $1,230.00 | $1,255.40 | 2.5M |
| Aug 20, 2026 | $1,274.13 | $1,280.28 | $1,243.2301 | $1,244.40 | 2.62M |
| Aug 19, 2026 | $1,245.81 | $1,292.65 | $1,240.54 | $1,280.34 | 4.54M |
| Aug 18, 2026 | $1,200.00 | $1,228.47 | $1,194.01 | $1,225.73 | 2.51M |
| Aug 17, 2026 | $1,175.20 | $1,198.52 | $1,163.50 | $1,183.16 | 1.81M |
The latest Smart Investors Daily articles mentioning LLY.
LLY research
Company profile and research snapshot.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HSBC | Reduce | — |
| Aug 7, 2026 | Truist Securities | Buy | — |
| Aug 6, 2026 | Wells Fargo | Overweight | — |
| Aug 6, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 15, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 12, 2026
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]
Benzinga · Sep 12, 2026
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
Yahoo · Sep 11, 2026
Morgan Stanley sees Eli Lilly taking share before semaglutide's patents even become the bigger issue.
Yahoo · Sep 11, 2026
AbbVie (ABBV) grew revenue 10.4% over the past twelve months and turned 33.9% of it into operating profit, second only to Eli Lilly among its peers on both counts. Its stock returned 24.9% over the same twelve months, fifth of the six. What the business delivered and what the market paid for it have come apart.
Interpretive context generated from the platform’s current data sources.
Eli Lilly and Company shares closed at $1,115.25, reflecting a daily decline of 1.66% per SID market data. Over the trailing one-month period, LLY has declined 8.57%, while the three-month return shows a loss of 3.9%. Despite near-term weakness, the stock has posted a 12.28% gain over the past twelve months. Technically, LLY is trading below its 50-day moving average of $1,184.65 but remains above its 200-day moving average of $1,059.75, indicating a potential near-term pullback within a longer-term uptrend. The 14-day RSI registers at an extremely oversold reading of 2.5, according to Massive/Polygon data, suggesting the stock may be approaching a technical inflection point. LLY's beta of 0.369 reflects significantly lower volatility than the broader market. Average daily trading volume stands at approximately 3.8 million shares, supporting a market capitalization of roughly $906.5 billion.
Eli Lilly and Company currently trades at a price-to-earnings ratio of 49.16, a substantial premium relative to the broader Healthcare sector, according to SID market data. The PEG ratio stands at 1.47, suggesting that while the P/E multiple is elevated, it remains relatively measured when adjusted for the company's expected earnings growth trajectory. The price-to-book ratio of 38.04 reflects the market's significant premium over Eli Lilly's net asset value, consistent with the company's asset-light pharmaceutical business model and robust intellectual property portfolio, per SEC filings. The company offers a dividend yield of approximately 0.59%, indicating a modest income component relative to its growth-oriented profile. These valuation metrics position Eli Lilly at the upper end of large-cap pharmaceutical valuations, driven primarily by investor expectations surrounding its GLP-1 receptor agonist franchise and pipeline development catalysts in metabolic and oncology therapeutics.
Eli Lilly's composite smart money score stands at 46 out of 100, registering a neutral signal according to SID market data. Institutional ownership conviction scores a perfect 25 out of 25, reflecting strong commitment from major asset managers and mutual fund complexes. In contrast, insider activity scores a modest 4.2 out of 25, though recent filings reveal 13 insider transactions over the past 90 days, per SEC Form 4 filings. Notably, insider purchases outnumber sales by a ratio of more than two to one, with 9 buys versus 4 sells recorded during that period. Dark pool activity scores 9.2 out of 25, indicating moderate levels of off-exchange institutional trading. Congressional trading interest registers at 7.6 out of 25, per 13F institutional filings and congressional disclosure records. The divergence between the high institutional conviction score and the neutral overall composite suggests that while large institutions maintain strong positions, other smart money indicators present a more mixed picture for LLY at current price levels.
Eli Lilly has delivered three consecutive quarters of earnings beats, according to company earnings reports. In the most recent reported quarter ending early 2026, the company posted EPS of $7.54 against a consensus estimate of $6.96, representing a $0.58 positive surprise. The following quarter saw an acceleration in outperformance, with actual EPS of $8.55 exceeding the $6.85 estimate by $1.70. The strongest beat occurred in the subsequent period, where Eli Lilly reported $8.38 per share versus analyst estimates of $6.01, delivering a $2.37 upside surprise. Looking ahead, analysts project EPS of $8.84 for the upcoming quarter with results expected on August 6, 2026, per analyst estimates. The consistent pattern of earnings outperformance, with surprise magnitudes expanding from $0.58 to $2.37, underscores the company's ability to exceed market expectations driven by accelerating revenue from its GLP-1 and incretin-based therapeutic portfolio.
Wall Street consensus on Eli Lilly remains predominantly constructive, with four of the five most recent analyst actions carrying bullish designations, per Wall Street analyst reports. Truist Securities reiterated a Buy rating on August 7, 2026, while both Wells Fargo and Cantor Fitzgerald maintained Overweight ratings on August 6, 2026, following the company's earnings release. Citigroup also reaffirmed a Buy rating on July 15, 2026, according to SID consensus data. The sole dissenting view comes from HSBC, which reiterated a Reduce rating on September 10, 2026, maintaining its cautious stance on the stock. Notably, all five ratings represent reiterations of prior positions rather than upgrades or downgrades, suggesting analysts are maintaining established convictions at current valuation levels. The four-to-one ratio of bullish-to-bearish ratings reflects broad Wall Street confidence in Eli Lilly's commercial execution and pipeline prospects, though the HSBC Reduce rating signals that valuation concerns persist among certain institutional research desks.
The latest Smart Investors Daily articles mentioning LLY.
